Fewer than one in 10 people who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it issues its first guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for broader and more equitable access to these injectable treatments.
Per forecasts, more than two billion will be obese by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a long-term condition that can be managed with comprehensive and continuous treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and supply-chain constraints are major barriers to widespread availability to the jabs that can aid individuals in losing considerable body mass, says the agency.
Skinny Jab Supply Crisis
Even in the present best projected outlook, the manufacturing of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, according to the WHO.
The recommendation encourages governments and firms to widen access, by strategies including patent sharing.
The intellectual property rights on semaglutide – the core component of the drug Wegovy – is set to lapse in multiple nations in 2026.
How Obesity Injections Operate
The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and increase satiety so individuals consume fewer calories.
Individuals commonly see weight reduction in the initial weeks of commencing the once-weekly jabs.
Evidence points to people may see weight return within a year of discontinuing the drug, as their typical food cravings return.
To be above a healthy weight raises your risk for contracting health problems, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns people in all nations and was associated with millions of fatalities worldwide in 2024, as per the WHO.
